Apixaban and dabigatran ... Rivaroxaban tied to higher bleeding rates vs. low-dose aspirin In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs.

PERIXa protocol shows minimal bleeding risk in AF patients, ensuring safe anticoagulation management for minor procedures.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 ... coupled with favorable price action and low valuation ratios, could attract value ...

Some patients I've treated for it have had no other symptoms apart from a very low heart rate ... (DOACs), such as ...

for stroke prevention in low-risk patients (CHA2DS2-VASc score of 0–1). Novel anticoagulants include dabigatran, rivaroxaban and apixaban. Based on the RE-LY study, a 150-mg dose of dabigatran ...

found that rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to low-dose aspirin, but rates were higher for rivaroxaban. These findings can help patients with atrial ...

Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab ... shares in first-line metastatic melanoma are in the low double digits for Opdualag," with some use of the drug also ...

Discover how botanical and nutrient therapies provided adjunctive support for a 76-year-old patient with treatment-resistant ...

Strengths of the study are the rigorous design and execution of the trial, with a long median duration of follow-up, low rate of loss to follow-up ... that provides robust evidence that reduced-dose ...